Apixaban for Extended Treatment of Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy. The study drugs were administered for 12 months. RESULTS: A total of 2486 patients underwent randomization, of whom 2482 were included in the intention-to-treat analyses. Symptomatic recurrent venous thromboembolism or death from venous thromboembolism occurred in 73 of the 829 patients (8.8%) who were receiving placebo, as compared with 14 of the 840 patients (1.7%) who were receiving 2.5 mg of apixaban (a difference of 7.2 percentage points; 95% confidence interval [CI], 5.0 to 9.3) and 14 of the 813 patients (1.7%) who were receiving 5 mg of apixaban (a difference of 7.0 percentage points; 95% CI, 4.9 to 9.1) (P<0.001 for both comparisons). The rates of major bleeding were 0.5% in the placebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group. The rates of clinically relevant nonmajor bleeding were 2.3% in the placebo group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group. The rate of death from any cause was 1.7% in the placebo group, as compared with 0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group. CONCLUSIONS: Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. (Funded by Bristol-Myers Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For the baseline risk of major bleeding, we used data from 2 randomized trials on people with VTE, showing that the risk of major bleeding with placebo during 18 or 24 months of follow-up was as low as 0.5% 306 and as high as 1.5% in 18 months. 259”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“We identified 2 RCTs 306,314 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Two of these agents, rivaroxaban and apixaban, have been studied at a reduced dose: from 20 mg daily to 10 mg daily for rivaroxaban and 5 mg to 2.5 mg twice daily for apixaban. 306,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
Citations
Cites
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
Self-citationApixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationAspirin for Preventing the Recurrence of Venous Thromboembolism
Becattini, C., Agnelli, G., Schenone, A., Eichinger, S., Bucherini, E., Silingardi, M., Bianchi, M., Moia, M., Ageno, W., Vandelli, M. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114238 · Cited by 620
Self-citation
Research works printed but not linked: 1
- Schulman S, 2011, J Thromb Haemost, 9, 22
Cited by
Items 501–600 of 1,000
Approach to the new oral anticoagulants in family practice: Part 1: comparing the options
Douketis, J. D., Bell, A., Eikelboom, J. W., & Liew, A. (2014) · Europe PMC (PubMed Central) · doi:10.25405/ncl.34238934 · Cited by 18
Direct oral anticoagulants: efficacy and safety in patient subgroups
Mavrakanas, T. A., Samer, C. F., Fontana, P., & Perrier, A. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14081 · Cited by 14
Direct Oral Anticoagulants and the Paradigm Shift in the Management of Venous Thromboembolism
Lim, H. Y., Nandurkar, H. H., & Ho, P. W. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1637750 · Cited by 15
The prevention of venous thromboembolism recurrence in the elderly: a still open issue
Palareti, G., & Poli, D. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1526667 · Cited by 14
Żuk, J., Papuga-Szela, E., Zaręba, L., & Undas, A. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-03012-7 · Cited by 17
Antonucci, E., Migliaccio, L., Abbattista, M., Caronna, A., Marchi, S. D., Giorgio, A. D., Giulio, R. D., Lerede, T., Garzia, M., Martinelli, I., et al. (2020) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029620945792 · Cited by 14
Riess, H. B., Verhamme, P. B., Weitz, J. I., Young, A., Bauersachs, R. M., Beyer‐Westendorf, J., Crowther, M. A., & Maraveyas, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103125 · Cited by 15
Self-citationPalareti, G., Antonucci, E., Legnani, C., Mastroiacovo, D., Poli, D., Prandoni, P., Tosetto, A., Pengo, V., Testa, S., & Ageno, W. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-040449 · Cited by 15
der Linden, L. R. V., Vanassche, T., Cutsem, E. V., Aelst, L. N. L. V., & Verhamme, P. B. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15785 · Cited by 16
“At the moment we have reassuring data from EINSTEIN CHOICE and AMPLIFY Extended that a lower dose in secondary VTE prevention provides similar thrombotic protection compared to a higher dose.(30,31) Two trials are currently ongoing, the API-CAT and EVE trials, where such data are being gathered on apixaban in the long…”
ResultAbdel‐Azeim, S., Oliva, R., Chermak, E., CRISTOFARO, R. D., & Cavallo, L. (2014) · Biochemistry · doi:10.1021/bi500770p · Cited by 14
New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism
den Exter, P. L., Kooiman, J., van der Hulle, T., & Huisman, M. V. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.004 · Cited by 14
Toth, P. P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s88088 · Cited by 19
Predictive Value of Mean Platelet Volume for Pulmonary Embolism Recurrence
Araz, Ö., Albez, F. S., Uçar, E. Y., Kerget, B., Yılmaz, N., & Akgün, M. (2017) · Lung · doi:10.1007/s00408-017-0020-7 · Cited by 14
Pritchard, E. R., Murillo, J. R., Putney, D. R., & Hobaugh, E. C. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217726158 · Cited by 14
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin
Prandoni, P., Lensing, A. W. A., Prins, M. H., Gebel, M., Pap, A. F., Homering, M., Bauersachs, R. M., Beyer‐Westendorf, J., Bounameaux, H., Cohen, A. T., et al. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.06.009 · Cited by 14
Self-citationApixaban to prevent stroke in patients with atrial fibrillation: a review
Peterson, B. E., Al‐Khatib, S. M., & Granger, C. B. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716652787 · Cited by 16
“73 m2 (as derived from the Cockcroft–Gault equation) [Agnelli et al. 2013].”
Wakefield, T. W., Andrea, T., & Henke, P. K. (2014) · Circulation · doi:10.1161/circulationaha.114.012235 · Cited by 16
Schenker, C., Stalder, O., Méan, M., Tritschler, T., Righini, M., Rodondi, N., & Aujesky, D. (2023) · Thrombosis and Haemostasis · doi:10.1055/s-0042-1760365 · Cited by 14
Sandblad, K. G., Schulman, S., Rosengren, A., Sörbo, J., Philipson, J., & Hansson, P. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13712 · Cited by 13
“In individual studies, there are differences in the safety benefits of different DOACs, with possibly the largest benefit for apixaban [7–11]; however, without head-to-head studies, it is not possible to draw firm conclusions.”
BackgroundPallazola, V. A., Kapoor, R. K., Kapoor, K., McEvoy, J. W., Blumenthal, R. S., & Gluckman, T. J. (2019) · Vascular Medicine · doi:10.1177/1358863x18819816 · Cited by 14
Assessment of a Pharmacist-Led Direct Oral Anticoagulant Monitoring Clinic
Haché, J., Bonsu, K. O., Chitsike, R. S., Nguyen, H. V., & Young, S. W. (2021) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v74i1.3035 · Cited by 18
Khan, F. A., Rahman, A. A., Tritschler, T., Carrier, M., Kearon, C., Weitz, J. I., Schulman, S., Couturaud, F., Becattini, C., Agnelli, G., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1690-8728 · Cited by 18
Self-citationDiagnostik und Therapie der Lungenembolie
Konstantinides, S., Mavromanoli, A. C., & Hobohm, L. (2021) · Herz · doi:10.1007/s00059-021-05078-3 · Cited by 14
Pulmonary embolism: current and new treatment options
Walter, R. J., Moores, L. K., & Jiménez, D. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.936931 · Cited by 13
New oral anticoagulants – a review
Ghanima, W., Atar, D., & Sandset, P. M. (2013) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.12.1111 · Cited by 18
“In long-term prophylaxis following initial anti-coagulation treatment, apixaban led to a significant reduction in the risk of recurrence of venous thrombosis compared with a placebo, without a significant increase in bleeding risk (21).”
BackgroundPotential new uses of non–vitamin K antagonist oral anticoagulants to treat and prevent stroke
Yaghi, S. R., Kamel, H., & Elkind, M. S. V. (2015) · Neurology · doi:10.1212/wnl.0000000000001817 · Cited by 13
“Assuming an annual recurrence rate of 3%, one would need 1,800 patients in each group (3,600 total) with average follow-up of 4 years to demonstrate a 25% relative reduction with NOACs vs warfarin for recurrent CVT, which is very difficult to perform given the low overall prevalence of CVT. Antiphospholipid antibody s…”
BackgroundUpdate on diagnosis and anticoagulant therapy for venous thromboembolism
Stevens, H., & Tran, H. A. (2018) · Internal Medicine Journal · doi:10.1111/imj.14063 · Cited by 13
Zwicker, J. I., & Bauer, K. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5184 · Cited by 15
Quon, P., Le, H. H., Raymond, V., Mtibaa, M., & Moshyk, A. (2016) · Journal of Medical Economics · doi:10.3111/13696998.2016.1141780 · Cited by 12
Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach
Cohen, A. T., & Black, S. A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1028 · Cited by 15
“Currently, two classes of NOACs have reached phase III trials and beyond- the direct thrombin (Factor IIa) inhibitor (dabigatran) (5–7) and the direct factor Xa inhibitors (rivaroxaban [8, 9], apixaban [10, 11], edoxaban [12]).”
BackgroundSelf-citationAn Update on the “Novel” and Direct Oral Anticoagulants, and Long-Term Anticoagulant Therapy
Djulbegovic, M., & Lee, A. I. (2018) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2018.04.010 · Cited by 14
Antithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_19 · Cited by 14
Ocak, G., Boenink, R., Noordzij, M., Bos, W. J. W., Vikse, B. E., Cases, A., Kerschbaum, J., Helve, J., Nordio, M., Arıcı, M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.7624 · Cited by 13
Role of apixaban (eliquis) in the treatment and prevention of thromboembolic disease.
Budovich, A., Zargarova, O., & Nogid, A. (2013) · Europe PMC (PubMed Central) · Cited by 20
Sehgal, V., Bajwa, S. S., & Bajaj, A. (2013) · Annals of Cardiac Anaesthesia · doi:10.4103/0971-9784.114244 · Cited by 12
Hull, R. D., & Gersh, M. H. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.975786 · Cited by 13
Ikeda, N., Amemiya, K., Sato, S., Iijima, R., Hara, H., & Nakamura, M. (2021) · Heart and Vessels · doi:10.1007/s00380-021-01799-x · Cited by 12
Agrawal, V., & Kim, E. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1111-2 · Cited by 15
Zou, H., Li, Y., & Xu, G. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1637-y · Cited by 12
“Apixaban, as a DOAC, provides an effective and safe regimen for the initial and long-term treatment of DVT and PE compared to conventional therapy (subcutaneous enoxaparin, followed by warfarin) and reduces the risk of recurrent DVT and PE compared to placebo following initial therapy [40, 41].”
BackgroundLow-Dose DOACs in Very High-Risk MPNs: Less Bleeding But More Arterial Thrombotic EventsPreprint
Herbreteau, L., Papageorgiou, L., Clech, L. L., Garcia, G., James, C., Pan‐Petesch, B., Couturaud, F., Gerotziafas, G., Lippert, É., & Ianotto, J. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4054506 · Cited by 12
Jugrin, A. V., Ustyugova, A., Urbich, M., Sunderland, T., & Lamotte, M. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1027 · Cited by 11
Drug therapy in anticoagulation: which drug for which patient?
Millar, C. M., & Laffan, M. A. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-3-233 · Cited by 11
Direct Oral Anticoagulants: Quick Primer on When to Use and When to Avoid
Bejjani, A., & Bikdeli, B. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2451-4014 · Cited by 18
Li, A., Khatib, R., Lopes, L. C., Aloweni, F. B. A. B., Lu, L., He, Q., Wu, J., Zhang, P., Tang, Y., Pavalagantharajah, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015371 · Cited by 14
Galanis, T., Keiffer, G., & Merli, G. J. (2014) · Current Therapeutic Research · doi:10.1016/j.curtheres.2014.06.002 · Cited by 12
“The Einstein-Acute DVT study was an open-label, randomized, event-driven, noninferiority trial comparing rivaroxaban (15 mg twice daily for the first 3 weeks followed by 20 mg once daily) to conventional anticoagulation therapy, which consisted of a lowmolecular-weight heparin followed by a vitamin K antagonist, in pa…”
MethodInfluentialJoyce, E. V., Haymart, B., Kong, X., Ali, M. A., Carrigan, M., Kaatz, S. S., Shah, V. I., Kline-Rogers, E. M., Kozłowski, J., Froehlich, J. B., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025471 · Cited by 11
Long-term Anticoagulation with Apixaban in Patients with Cerebral Venous Thrombosis
Bharath, S. P., Arshad, H., Song, Y., & Kirmani, J. F. (2023) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296221129591 · Cited by 11
“5 mg twice daily for VTE treatment (pulmonary embolism or deep venous thrombosis) after six to twelve months of anticoagulation and found no difference.(8) However, there is no comparable trial evaluating safety and efficacy of these two doses in CVT after six to twelve months of treatment.”
BackgroundMerali, S. J., Byon, W., Patel, Y. T., Elsrougy, A., Marchisin, D., Perera, V., Chen, W., He, B., & Murthy, B. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12935 · Cited by 11
Beyer‐Westendorf, J., Cohen, A. T., & Monréal, M. (2015) · European Heart Journal Supplements · doi:10.1093/eurheartj/suv034 · Cited by 13
Self-citationTreatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies
Weitz, J. I., & Khorana, A. A. (2018) · Thrombosis and Haemostasis · doi:10.1160/th17-09-0681 · Cited by 11
Self-citationPalareti, G., Bignamini, A. A., Cini, M., Li, Y.-J., Urbanek, T., Maďarič, J., Bouslama, K., Юрьевич, С. Г., Andreozzi, G. M., Matuška, J., et al. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02765-1 · Cited by 11
Singh, B. B., Pai, P., Kumar, H., George, S., Mahapatra, S., Garg, V., Gupta, G. N., Makineni, K., Ganeshwala, G., Narkhede, P., et al. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00254-w · Cited by 11
“The efficacy of twice daily dose of apixaban was observed in AMPLIFY and AMPLIFY-EXT study [23, 24].”
BackgroundLee, Y. J. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s72268 · Cited by 12
“Secondary prevention of VTE For patients with VTE who have received treatment with an anticoagulant for 3–12 months and were in clinical equipose about continuation or cessation of anticoagulant therapy, extended therapy Phase III trials were conducted for secondary prevention of VTE (Table 2).(28,35,36) Dabigatran tr…”
Provoked vs minimally provoked vs unprovoked VTE: does it matter?
Becattini, C., & Cimini, L. A. (2023) · Hematology · doi:10.1182/hematology.2023000492 · Cited by 10
Anticoagulation in the Management of Acute Pulmonary Embolism—A Review
del Toro-Mijares, R., Murguía, A. R., Porres‐Aguilar, M., & Mukherjee, D. (2024) · International Journal of Angiology · doi:10.1055/s-0044-1782537 · Cited by 4
Porada, M., & Bułdak, Ł. (2025) · Metabolites · doi:10.3390/metabo15020072 · Cited by 12
Direct Oral Anticoagulants in the Treatment of Venous Thromboembolic Disease
Febres, L. M. S., & Manteca, J. C. (2017) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2017.01.010 · Cited by 11
“1% with apixaban 5 mg 178 (Table 3).(29) 179 In recent years, several meta-analyses have examined the safety and 180 efficacy profile of several DOACs in the treatment of VTED.”
BackgroundGoshgarian, C., & Gorelick, P. B. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0782-6 · Cited by 10
Imberti, D., Pomero, F., & Mastroiacovo, D. (2020) · Blood transfusion · doi:10.2450/2019.0265-18 · Cited by 12
George, C., Rahman, M., & Monagle, P. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00403-5 · Cited by 10
“Randomized trials in adults include the AMPLIFY and AMPLIFY-EXT trials [91, 92], which showed that apixaban was noninferior to standard therapy, with lower rates of bleeding complications, thus demonstrating that apixaban is safe for acute and extended treatment of VTE in adults.”
Management of venous thromboembolism in athletes
Swan, D., Carter‐Brzezinski, L., & Thachil, J. V. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100780 · Cited by 10
García-Escobar, I., Brozos-Vázquez, E., Abad, D. G., Martínez-Marín, V., Pachón, V., & Martín, A. J. M. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02506-4 · Cited by 13
Direct Oral Anticoagulants: A Review for the Non-Specialist
Gunawardena, T. (2021) · Hematology Reports · doi:10.4081/hr.2021.9239 · Cited by 10
Park, H., Jones, B. L., Huang, P., Kang, H., Dietrich, E. A., DeRemer, C. E., & Lo‐Ciganic, W. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231155489 · Cited by 11
Oo, T. H., & Zalpour, A. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s51006 · Cited by 10
“5 mg twice daily and 5 mg twice daily reduced the risk for recurrent VTE without increasing risk for bleeding.(33)”
Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan
Nakamura, M., Yamada, N., & Ito, M. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17005 · Cited by 13
Pulmonary Embolism: Contemporary Medical Management and Future Perspectives
Barco, S., & Konstantinides, S. (2018) · Annals of Vascular Diseases · doi:10.3400/avd.ra.18-00054 · Cited by 12
Lamsam, L. A., Sussman, E. S., Iyer, A., Bhambhvani, H. P., Han, S. S., Skirboll, S. L., & Ratliff, J. K. (2018) · Stroke · doi:10.1161/strokeaha.118.022156 · Cited by 10
Komiyama, S., Nagashima, M., Taniguchi, T., Rikitake, T., & Morita, M. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00757-w · Cited by 10
Cappato, R., Chiarito, M., Giustozzi, M., Briani, M., Ali, H., Riva, L., Bonitta, G., Lodigiani, C., Furlanello, F., Balla, C., et al. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.09.007 · Cited by 10
Lal, A., Mukhtar, O., Chalmers, S. J., Karp, J. D., Wieruszewski, P. M., & Park, J. G. (2022) · Hospital Pharmacy · doi:10.1177/00185787221122656 · Cited by 10
“The median age for patients on DOAC therapy was 69 years [IQR 59-78] years, with a median APACHE III score at 24 hours of 64 [51-78] and Charlson’s comorbidity score 4 [5-11].”
MethodLui, B., Wee, B., Lai, J., Khattak, Z., Kwok, A., Donarelli, C., Ho, P. W., & Lim, H. Y. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.09.006 · Cited by 11
The treatment of venous thromboembolism with novel oral anticoagulants: warnings and limitations.
Prandoni, P. (2015) · PubMed · doi:10.2450/2015.0002-15 · Cited by 10
Anticoagulating patients with high-risk acquired thrombophilias
Skeith, L. (2018) · Hematology · doi:10.1182/asheducation-2018.1.439 · Cited by 11
Direct Oral Anticoagulants: Novel Approach for the Treatment of Thrombosis in Pediatric Patients?
Mikler, J., Samoš, M., Bolek, T., Škorňová, I., Stančiaková, L., Staško, J., & Mokáň, M. (2019) · Pediatric Cardiology · doi:10.1007/s00246-019-02159-3 · Cited by 10
Paraneoplastic Thromboembolism and Thrombophilia: Significance in Visceral Medicine
Pfrepper, C. (2020) · Visceral Medicine · doi:10.1159/000509150 · Cited by 10
Parakh, R., Krishna, P. R., Amin, P. R., Bedi, V., Desai, S., Dumra, H. S., Gupta, P., Gupta, V. G., Hydrabadi, R., Kamerkar, D. R., et al. (2016) · PubMed · Cited by 10
Ahuja, T., Raco, V., Papadopoulos, J., & Green, D. (2021) · PubMed · doi:10.1097/pts.0000000000000535 · Cited by 13
The advent of the novel oral anticoagulants
Prandoni, P. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.210 · Cited by 9
Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis
Attard, L. M., Gatt, A., Bertoletti, L., Delluc, A., & Riva, N. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s271411 · Cited by 10
Anticoagulation and compression therapy for proximal acute deep vein thrombosis
Palareti, G., Santagata, D., Ponti, C. D., Ageno, W., & Prandoni, P. (2024) · VASA · doi:10.1024/0301-1526/a001138 · Cited by 9
Cohen, A. T., Dhamane, A. D., Liu, X., Singh, R., Han, S. C.-H., Stellhorn, R., Wang, J., & Luo, X. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7016 · Cited by 9
Self-citationThe new oral anticoagulants: clinical use and reversal agent development
Costin, J. C., Ansell, J., Bakhru, S., Laulicht, B., & Steiner, S. S. (2015) · ISBT Science Series · doi:10.1111/voxs.12160 · Cited by 9
Accidents hémorragiques des nouveaux anticoagulants oraux et examens de la coagulation
Samama, M. M., Conard, J., & Louët, A. L. (2013) · Journal des Maladies Vasculaires · doi:10.1016/j.jmv.2013.05.005 · Cited by 9
“[4] Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al.”
BackgroundThe Role of New Oral Anticoagulants (NOACs) in Cancer Patients
Ravikumar, R., Lim, C. S., & Davies, A. H. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_112 · Cited by 10
Bradbury, C. A., Buckley, T., Sun, Y. Z., Rose, P. E., & Fitzmaurice, D. A. (2019) · EClinicalMedicine · doi:10.1016/j.eclinm.2019.11.011 · Cited by 9
“5 mg bd has demonstrated a comparable incidence of major bleeding to placebo [8] and rivaroxaban (10 mg od or 20mg od) a comparable bleeding risk to aspirin [9].”
BackgroundAGO104 is a RdDM effector of paramutation at the maize b1 locus
Aubert, J., Bellegarde, F., Oltehua‐López, O., Leblanc, O., Arteaga-Vazquez, M. A., Martienssen, R. A., & Grimanelli, D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273695 · Cited by 9
Transgender Medicine and Risk of Venous Thromboembolism
van Bunderen, C. C., Leentjens, J., & Middeldorp, S. (2022) · Hämostaseologie · doi:10.1055/a-1891-8158 · Cited by 9
Chatani, R., Yamashita, Y., Morimoto, T., Muraoka, N., Umetsu, M., Nishimoto, Y., Takada, T., Ogihara, Y., Nishikawa, T., Ikeda, N., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae028 · Cited by 9
“The doses of the direct oral anticoagulants ( DOACs) could be a clinically relevant issue for extended anticoagulation therapy in patients with VTE, 9 , 10 which might also be important in patients with cancer-associated VTE.”
BackgroundUpdate in venous thromboembolism pathophysiology, diagnosis, and treatment for surgical patients
Coleman, D. M., Andrea, T., & Henke, P. K. (2015) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2015.04.003 · Cited by 9
Amin, A., Jing, Y., Trocio, J. N., Lin, J., Lingohr-Smith, M., & Graham, J. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1158-2 · Cited by 9
The discovery of dabigatran etexilate for the treatment of venous thrombosis
Feuring, M., & van Ryn, J. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1188077 · Cited by 13
“ity of NOACs inhibit FXa, including rivaroxaban [14], apixaban [9,27], and edoxaban [15].”
BackgroundJaffer, I., & Weitz, J. I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00149-9 · Cited by 9
Self-citationKommission für Klinische Kardiovaskuläre Medizin der, D. G. K., Konstantinides, S., Lankeit, M., Erbel, C., & Tiefenbacher, C. (2020) · Der Kardiologe · doi:10.1007/s12181-020-00389-x · Cited by 10
“Im Falle einer verlängerten Antikoagulation mit Apixaban oder Rivaroxaban sollte die Dosis dieser NOAK um die Hälfte, entsprechend auf 2,5mg Apixaban 2-mal täglich oder 10mg Rivaroxaban 1-mal täglich, reduziert werden [38, 39].”
BackgroundDeCamillo, D., Haymart, B., & Barnes, G. D. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02573-6 · Cited by 9
Bikdeli, B., Khairani, C. D., Barns, B. M., Rosovsky, R. P. G., Jiménez, D., Monréal, M., Sylvester, K. W., Middeldorp, S., Bates, S. M., Krumholz, H. M., et al. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106714 · Cited by 10
Clinical Studies with Anticoagulants that Have Changed Clinical Practice
Hirsh, J., de Vries, T. A. C., Eikelboom, J. W., Bhagirath, V. C., & Chan, N. (2023) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1760330 · Cited by 10
Antithrombotika und Antihämorrhagika
Hein, L. (2011) · Springer eBooks · doi:10.1007/978-3-642-21992-4_15 · Cited by 9
Apixaban and oral implications
López-Galindo, M. P., & Sebastián, J. V. B. (2015) · Journal of Clinical and Experimental Dentistry · doi:10.4317/jced.52470 · Cited by 10
“AMPLIFY-EXT and ADOPT failed to specify the trial phase involved (11,15-17,24,25).”
BackgroundDrug Treatment of Venous Thromboembolism in the Elderly
Boey, J. P., & Gallus, A. S. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0378-x · Cited by 9
Self-citation
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- McMaster University (CA)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 699-708
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139785591
- Cited by
- 1,366
- References
- 19
- Citations by year
- 2026: 70 · 2025: 80 · 2024: 64 · 2023: 68 · 2022: 90 · 2021: 98 · 2020: 101 · 2019: 114 · 2018: 103 · 2017: 89 · 2016: 109 · 2015: 133 · 2014: 141 · 2013: 102
- FWCI
- 81.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Bayer HealthCare
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, venous thromboembolism, long-term anticoagulation, factor Xa inhibitors, recurrent venous thromboembolism, thromboprophylaxis, major bleeding, mortality, dose comparison, oral anticoagulants, clinical equipoise, post-thrombotic syndrome, pulmonary embolism, deep vein thrombosis
- MeSH terms
- Adult, Aged, Creatinine, Double-Blind Method, Female, Fibrinolytic Agents, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Recurrence, Treatment Outcome, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.